STAT+: Pharmalittle: Vertex exec says prices for gene therapies are ‘in the ballpark’; insulin access in poor countries remains spotty
Multimillion-dollar prices for a rival’s treatments with the potential to cure rare diseases are “in the right ballpark,” said Vertex's COO.
Rise and shine, everyone, another busy day is on the way. And this is especially true for us, since we hit the proverbial pause
